Eun Jung Song;Jae Kyeon;Ji Hyun Park;Mi La Cho;Jin Sil Park;Hye Jwa Oh;Ki Won Jo;Young Woo Park;Min Ji Seo;Ho Youn Kim;Jong-Ho Lee;Sun Jung Cho;Sun-Ha Yoon;Srok Ho Yoo;Yun Ju Woo;Jung Yu;Mi Kyung Park
发明人:
Young Woo Park,Ki Won Jo,Srok Ho Yoo,Jung Yu,Sun-Ha Yoon,Ji Hyun Park,Eun Jung Song,Jong-Ho Lee,Min Ji Seo,Sun Jung Cho,Mi La Cho,Ho Youn Kim,Mi Kyung Park,Hye Jwa Oh,Jin Sil Park,Yun Ju Woo,Jae Kyeon
申请号：
US13635874
公开号：
US20130022642A1
申请日:
2011.03.18
申请国别(地区):
US
年份:
2013
代理人:
摘要：
The present invention relates to TNFR2-IL21R fusion protein acting as a double-antagonist to TNF-alpha (α) and IL-21. The composition containing the double antagonist to TNF-α and Il-21 (TNFR2-IL21R fusion protein), known as major causes of autoimmune rheumatoid arthritis, one of autoimmune diseases, can reduce the secretion of inflammatory cytokine, increase the secretion of anti-inflammatory cytokine, and suppress the differentiation of osteoclasts better than single proteins such as TNFR2-Fc and IL21R-Fc. The TNFR2-IL21R fusion protein of the present invention has not only excellent treatment effect on arthritis in CIA mouse model not also excellent treatment effect on autoimmune rheumatoid arthritis by increasing the expression of Treg, the immune suppressive cells. Therefore, the TNFR2-IL21R fusion protein of the present invention can be effectively used as an active ingredient for the composition for the prevention and treatment of autoimmune disease.
